Brain Metastases

European Handbook of Neurological Management: Second Edition

Volumn 1, Issue , 2010, Pages 437-445

  Soffietti, R ^a   Cornu, P ^b   Delattre, J Y ^c   Grant, R ^d   Graus, F ^e   Grisold, W ^f   Heimans, J ^g   Hildebrand, J ^h   Hoskin, P ⁱ   Kalljo, M ^j   Krauseneck, P ^k   Marosi, C ^l   Siegal, T ^m   Vecht, C ⁿ  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e Thorax Institute   (Spain)

^f KAISER FRANZ JOSEF HOSPITAL   (Austria)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h Mount Vernon Hospital and University ^*

ⁱ MOUNT VERNON HOSPITAL   (United Kingdom)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k Vienna General Hospital and University   (Germany)

^l UNIVERSITY OF VIENNA   (Austria)

^m HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁿ MEDICAL CENTER HAAGLANDEN   (Netherlands)

more..

Author keywords

Anticoagulant therapy, standard treatment for acute venous thromboembolism (VTE) in cancer patients; Brain metastases; Dexamethasone, used to control cerebral oedema; Headache, focal neurological deficits and seizures most common presenting symptoms; Molecularly targeted therapies investigated in recent years, in patients with brain metastases; Primary objective, evidence based guidelines management of patients with brain metastases; Stereotactic radiosurgery (SRS) permitting delivery of single high dose of radiation; Treatment of multiple brain metastases; Treatment of single brain metastasis; Whole brain radiotherapy alone

Indexed keywords

EID: 84885520882     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444328394.ch30     Document Type: Chapter

References (59)

1. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51.
2. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70: 510-4.
3. Meyers CA, Smith JA, Bezjak A. Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22: 157-65.
4. Rudà R, Borgognone M, Benech F, Vasario E, Soffietti R. Brain metastases from unknown primary tumor. J Neurol 2001; 248: 394-8.
5. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur J Neurol 2004; 11: 577-81.
6. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CT in patients with brain metastases. J Neurooncol 1999; 44: 275-81.
7. Sze G, Johnson C, Kawamura Y, et al. Comparison of singleand triple-dose contrast material in the MR screening of brain metastases. AJNR 1998; 19: 821-8.
8. Desprechins B, Stadnik T, Koerts G, et al. Use of diffusion-weighted MR imaging in the differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. AJNR Am J Neuroradiol 1999; 20: 1252-7.
9. Hartmann M, Jansen O, Heiland S, et al. Restricted diffusion within ring enhancement is not pathognomonic for brain abscess. AJNR Am J Neuroradiol 2001; 22: 1738-42.
10. Van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumor: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatr 1996; 61: 321-3.
11. Klee B, Law I, Hoigaard L, Kosteljanetz M. Detection of unknown primary tumours in patients with cerebral metastases using whole-body 18F-fiuorodeoxyglucose positron emission tomography. Eur J Neurol 2002; 9: 657-62.
12. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnof sky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1996; 44: 675-80.
13. Cairncross JG, Posner JB. The management of brain metastases. In: Walker MD (ed.) Oncology of the Nervous System Boston: Martinus Nijhoff, 1983; pp. 342-77.
14. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886-93.
15. Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996; 5: 291-8.
16. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
17. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in cancer. N Engl J Med 2003; 349: 146-53.
18. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
19. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33: 583-90.
20. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78: 1470-6.
21. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006; 24: 1289-94.
22. Kelly K, Bunn PA. It is time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998; 20: 85-91.
23. Suki D, Abouassi H, Patel AJ, et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 2008; 108: 248-57.
24. Baumert BG, Rutten I, Dehing-Oberije C, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 2006; 66: 187-94.
25. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000; 47: 291-8.
26. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005; 63: 37-46.
27. Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 2005; 23: 8870-6.
28. Fuentes S, Delsanti C, Metellus P, et al. Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 2006; 58: 37-42.
29. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG randomised trial. Lancet 2004; 363: 1665-72.
30. Soffietti R, Costanza A, Laguzzi E, Nobile M, RudàR. Radiotherapy and chemotherapy of brain metastases. J Neuro-Oncol 2005; 75: 1-12.
31. Rades D, Kueter JD, Veninga T, Gliemroth J, Schild SE. Whole brain radiotherapy plus stereotactic radiosurgery (WBRT + SRS) versus surgery plus whole brain radiotherapy (OP + WBRT) for 1-3 brain metastases: results of a matched pair analysis. Eur J Cancer 2009; 45: 400-4.
32. Williams BJ, Suki D, Fox BD, et al. Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg 2009; 111: 439-48.
33. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96: 191-7.
34. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2004; 54: 1111-7.
35. Borgelt BB, Gelber RD, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1-9.
36. Hoskin PJ, Brada M. Radiotherapy for brain metastases. Clin Oncol 2001; 13: 91-4.
37. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53: 519-26.
38. Regine WF, Huhn JL, Patchell RA, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002; 52: 333-8.
39. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single brain metastases to the brain. JAMA 1998; 280: 1485-9.
40. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus wholebrain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-91.
41. Muller RP, Soffietti R, Abacioglu MU, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2009; 27: 89s.
42. De Angelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789-96.
43. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who receieved either whole brain radiotheraphy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007; 68: 1388-95.
44. Sawrie SM, Guthrie BL, Spencer SA, et al. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 2007; 70: 181-6.
45. Soltys SG, Adlwer JR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2007; 70: 187-93.
46. Rogers LR, Rock JP, Sills AK, et al. Results of a phase II trial of the GliaSite Radiation Therapy System for treatment of newly diagnosed, resected single brain metastases. J Neurosurg 2006; 105: 375-84.
47. Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol 2003; 16: 129-34.
48. Gutiérrez AN, Westerly DC, ToméWA, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 2007; 69: 589-97.
49. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009; 73: 1069-76.
50. Scott C, Suh J, Stea B, et al. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007; 30: 580-7.
51. Pollock BE, Brown PD, Foote RL, et al. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neuro Oncol 2003; 61: 73-80.
52. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase 2 randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644-50.
53. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase 2 trial. Int J Radiation Oncology Biol Phys 2005; 61: 185-91.
54. Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007; 13: 3637-41.
55. Soffietti R, RudàR, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008; 20: 676-84.
56. Ceresoli G, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-7.
57. Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J Clin Oncol 2007; 25: 5024-6.
58. Shimato S, Mitsudomi T, Kosaka T, et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neurooncology 2006; 8: 137-44.
59. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-9.